Business Context and Reporting Period
Company: Enlivex Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: May 2024 (Closing date: May 29, 2024)
Principal Office: Nes Ziona, Israel
The filing reports the completion of a registered direct offering (the "Offering") entered into on May 27, 2024, and closed on May 29, 2024, with a single institutional investor.
Key Financial Metrics
Capital Raised: The Offering consisted of 2,060,000 Ordinary Shares, 1,511,429 Pre-Funded Warrants, and associated Investor Warrants (Series A and Series B).
Net Proceeds: Approximately $4.5 million after deducting placement agent fees and estimated expenses.
Use of Proceeds: Working capital and general corporate purposes.
Placement Agent Fees: H.C. Wainwright & Co. received a cash fee of 7.0% of gross proceeds, a management fee of 1.0% of gross proceeds, plus reimbursement for expenses and clearing fees.
Other Financial Data: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics outside of the Offering proceeds.
Material Changes
The primary material change is the dilution of existing shareholders due to the issuance of new equity and warrants. The Offering structure includes:
- Ordinary Shares: 2,060,000 shares sold at $1.40 per share.
- Pre-Funded Warrants: 1,511,429 warrants sold at $1.399 per warrant with an exercise price of $0.001.
- Investor Warrants:
- Series A: 3,571,429 warrants exercisable at $1.40; expire 18 months post-issuance or 60 days after positive topline results for the ENX-CL-05-001 trial.
- Series B: 3,571,429 warrants exercisable at $1.40; expire 5.5 years post-issuance or 60 days after FDA filing for Allocetra TM osteoarthritis indication.
- Placement Agent Warrants: 250,000 warrants (Series A and B) issued to H.C. Wainwright & Co. at an exercise price of $1.75.
Outlook, Risks, and Management Commentary
Management Commentary: The Company intends to utilize the net proceeds for working capital and general corporate purposes to support ongoing operations and development.
Key Risks and Contingencies:
- Warrant Expiration Triggers: The Series A and Series B warrants have accelerated expiration dates tied to clinical milestones (positive topline results for knee osteoarthritis) and regulatory filings (FDA approval filing).
- Ownership Caps: Investor Warrants are subject to a 4.99% beneficial ownership limit (increasable to 9.99% at the holder's option). Pre-Funded Warrants are subject to a 9.99% limit.
- Dilution: The issuance of shares and warrants will increase the total share count, potentially diluting existing shareholders.
Investor Verification Checklist
- Verify the exact gross proceeds raised by calculating the weighted average price of shares and warrants sold.
- Confirm the current total share count and the percentage dilution resulting from the 2,060,000 new shares and potential warrant exercises.
- Review the status of the ENX-CL-05-001 trial to assess the likelihood of the Series A warrant expiration trigger.
- Examine the Company's cash runway post-Offering to determine if additional capital raises will be required before the next major milestone.
- Check the specific terms of the "customary adjustments" for the warrants to understand potential future dilution scenarios.